Dupilumab Treatment for Asthma: On the Road to a New Horizon Beyond Ethnic Differences?
Author:
Affiliation:
1. Department of Internal Medicine, Catholic Kwandong University College of Medicine, Incheon, Korea.
2. Department of Internal Medicine, Inha University School of Medicine, Incheon, Korea.
Funder
Inha University Hospital
Publisher
The Korean Academy of Asthma, Allergy and Clinical Immunology and The Korean Academy of Pediatric Al
Subject
Pulmonary and Respiratory Medicine,Immunology,Immunology and Allergy
Link
https://e-aair.org/pdf/10.4168/aair.2022.14.2.147
Reference14 articles.
1. Evaluation and Management of Difficult-to-Treat and Severe Asthma: An Expert Opinion From the Korean Academy of Asthma, Allergy and Clinical Immunology, the Working Group on Severe Asthma
2. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
3. Dupilumab in Persistent Asthma with Elevated Eosinophil Levels
4. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial
5. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. An early Indian experience with benralizumab - A compendium on severe asthma cases: a case series;F1000Research;2023-09-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3